Aurinia Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
LUPKYNIS sales grew 25% year-over-year in 2025, driving a 20% revenue increase and a dramatic rise in net income, aided by a significant tax benefit. 2026 guidance projects continued double-digit growth, with new clinical programs advancing and competition expected to expand the market.
-
LUPKYNIS sales surged 27% year-over-year in Q3 2025, prompting a second upward revision of 2025 guidance. New clinical data reinforced LUPKYNIS's efficacy and safety, while Aritinercept advanced toward clinical studies in two autoimmune diseases.
-
Q2 2025 saw 22% revenue growth and a sharp rise in net income, driven by LUPKYNIS sales and operational efficiency. Full-year guidance was raised, and positive Aritinercept phase I results support further clinical expansion.
-
Aritinercept's phase I study showed strong safety and robust, lasting reductions in immunoglobulins, supporting once-monthly dosing. The drug demonstrated superior potency and binding affinity versus competitors, and further studies in autoimmune diseases are planned for later this year.
-
Q1 2025 saw 24% revenue growth and a return to profitability, driven by Lupkynis sales and operational efficiency. Guidance for 2025 is reaffirmed, with continued focus on Lupkynis growth, patent defense, and upcoming AUR-200 phase I data.
Fiscal Year 2024
-
Q4 and full year 2024 saw strong revenue and Lupkynis sales growth, with improved profitability and cash flow following strategic restructuring. 2025 guidance projects continued growth, while AUR-200 development advances with phase I data expected in Q2 2025.
-
Q3 2024 saw record revenue and net income, driven by strong LUPKYNIS growth and operational efficiency. A major restructuring aims to boost focus and save $40M+ annually, while Japanese approval of LUPKYNIS triggered a $10M milestone payment.
-
Revenue and cash flow targets remain on track, with global expansion and label growth supporting the main product. Pipeline asset AUR-200 advances in early clinical studies, with a focus on B-cell-mediated diseases and strategic market selection.
-
Q2 2024 saw 38% revenue growth year-over-year, strong free cash flow, and a narrowed full-year guidance to $210–$220 million. LUPKYNIS patient base expanded 22%, and AUR200 advanced to clinical trials, with robust cash reserves and ongoing share repurchases.
-
LUPKYNIS continues to drive strong revenue growth, with 2024 guidance of $200–$220 million and cash flow positivity expected in Q2. Market expansion is supported by improved diagnosis, patient support, and robust clinical data, while pipeline assets and global partnerships offer future growth potential.